Results 21 to 30 of about 25,818 (186)

Induction of MET Receptor Tyrosine Kinase Down-Regulation through Antibody-Mediated Receptor Clustering [PDF]

, 2019
The proto-oncoprotein MET is a receptor tyrosine kinase that plays a key role in cancer cell growth and invasion. We have used fluorescence-tagged antibodies to activate MET in live serum-starved glioblastoma cells and monitor the fate of antibody-bound ...
Adam Dick, Fei Lu, Hong Sun, Hui Zhang, Wenjing Li   +4 more
core   +3 more sources

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study

Journal of Translational Medicine, 2019
Background MET amplification is associated with acquired resistance to first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in treating non-small-cell lung cancer (NSCLC); however, the therapeutic strategy in these ...
Wenxian Wang, Hong Wang, Peihua Lu, Zongyang Yu, Chunwei Xu, Wu Zhuang, Zhengbo Song   +6 more
doaj   +1 more source

Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer. [PDF]

, 2015
BackgroundPemetrexed is approved in the treatment of advanced stage nonsquamous non-small-cell lung cancer (NSCLC). The length of response is variable, and we thus sought to identify which clinicopathologic characteristics are associated with long-term ...
Liang, Ying, Neal, Joel W, Wakelee, Heather A   +2 more
core   +1 more source

Enhancing the Radiation Response in KRAS Mutant Colorectal Cancers Using the c-Met Inhibitor Crizotinib

Translational Oncology, 2019
INTRODUCTION: C-Met plays important roles in treatment resistance, tumor invasion, and metastasis. In this study, we used a small molecule inhibitor of c-Met, crizotinib, in cetuximab-resistant, mutant KRAS-driven colorectal cancer cell lines and ...
Kyle C. Cuneo, Ranjit K. Mehta, Himabindu Kurapati, Dafydd G. Thomas, Theodore S. Lawrence, Mukesh K. Nyati   +5 more
doaj   +1 more source

Successful role of adjuvant radiotherapy in a rare case of tracheal inflammatory myofibroblastic tumor: a case report [PDF]

, 2019
BACKGROUND:: Inflammatory myofibroblastic tumor (IMT) is a rare benign cancer that can express a more aggressive phenotype related to the genetic mutation of the anaplastic lymphoma kinase receptor (ALK). Involvement of trachea is extremely rare and due
Abate, Gessica, Bulzonetti, Nadia, D’Urso, Pasqualina, Lisi, Roberto, Marampon, Francesco, Martinetti, Maria Teresa, Siniscalchi, Benedetta, Tombolini, Vincenzo   +7 more
core   +1 more source

Alpha-tocopherol attenuates the anti-tumor activity of crizotinib against cells transformed by NPM-ALK.

PLoS ONE, 2017
Anaplastic large cell lymphomas (ALCL) are mainly characterized by harboring the fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK).
Yuki Uchihara, Fumihito Ueda, Kenji Tago, Yosuke Nakazawa, Tomoyuki Ohe, Tadahiko Mashino, Shigenobu Yokota, Tadashi Kasahara, Hiroomi Tamura, Megumi Funakoshi-Tago   +9 more
doaj   +1 more source

A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases. [PDF]

, 2017
A challenge in precision medicine requires identification of actionable driver mutations. Critical to such effort is the deployment of sensitive and well-validated assays for mutation detection.
Ali, Siraj, Bergsland, Emily K, Bivona, Trever G, Damato, Bertil, Fogh, Shannon, Miller, Vincent A, Urisman, Anatoly, Wang, Victoria E, Wolfe, John, Young, Lauren   +9 more
core   +1 more source

Successful Treatment of Crizotinib-Induced Fulminant Liver Failure: A Case Report and Review of Literature

Case Reports in Hepatology, 2020
Crizotinib is a first-line tyrosine kinase inhibitor used for the treatment of metastatic lung cancer. Crizotinib-induced hepatotoxicity is a rare event. We report a case of a 46-year-old female with a history of metastatic lung cancer who presented with
Kyle Kreitman, Satheesh P. Nair, Jiten P. Kothadia   +2 more
doaj   +1 more source

Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report

Case Reports in Oncology, 2016
Crizotinib, the first clinically available inhibitor of anaplastic lymphoma kinase (ALK) gene rearrangement, is generally well tolerated. In contrast, neutropenia induced by crizotinib is a commonly reported grade 3 or 4 adverse event.
Jun Osugi, Yuki Owada, Takumi Yamaura, Satoshi Muto, Naoyuki Okabe, Yuki Matsumura, Mitsunori Higuchi, Hiroyuki Suzuki, Mitsukazu Gotoh   +8 more
doaj   +1 more source

Entrectinib for ROS1‐rearranged non‐small cell lung cancer after crizotinib‐induced interstitial lung disease: A case report

Respirology Case Reports, 2021
Chromosomal rearrangements involving the c‐ros oncogene 1 (ROS1) are identified in approximately 1% of non‐small cell lung cancer (NSCLC) patients. Crizotinib is the first tyrosine kinase inhibitor (TKI) against ROS1‐rearranged NSCLC. G2032R, a secondary
Mai Tanimura, Nobutaka Kataoka, Yusuke Kunimatsu, Rei Tsutsumi, Izumi Sato, Takayuki Nakano, Keiko Tanimura, Takayuki Takeda   +7 more
doaj   +1 more source